Literature DB >> 16127037

Risk factors for acquisition of multidrug-resistant Pseudomonas aeruginosa producing SPM metallo-beta-lactamase.

Simone Aranha Nouér1, Marcio Nucci, Márcia P de-Oliveira, Flávia Lúcia Piffano Costa Pellegrino, Beatriz Meurer Moreira.   

Abstract

To evaluate risk factors for colonization or infection due to multidrug-resistant Pseudomonas aeruginosa (MDRPa) carrying the bla(SPM) gene (SPM-MRDPa) among hospitalized patients, we undertook a case control study at a 480-bed, tertiary-care university hospital. Two different case definitions were used. In the first definition, a case patient (SPM case patient) was defined as a patient who had at least one isolate of SPM-MDRPa (14 patients). In the second, a case patient (non-SPM case patient) was defined as a patient who had at least one isolate of non-SPM-MDRPa (18 patients). For each case patient, we selected two controls, defined as a patient colonized and/or infected by a non-MDRPa isolate during the same study period and with the closest duration of hospitalization until the isolation of P. aeruginosa as cases. The use of quinolones was the single independent predictor of colonization and/or infection by bla(SPM) MDRPa (odds ratio [OR] = 14.70, 95% confidence interval [95% CI] = 1.70 to 127.34, P = 0.01), whereas the use of cefepime was the single predictor of colonization and/or infection by non-bla(SPM) MDRPa (OR = 8.50, 95% CI = 1.51 to 47.96, P = 0.01). The main risk factor for MDRPa was a history of antibiotics usage. Stratification of risk factor analysis by a precise mechanism of resistance led us to identify a specific antibiotic, a quinolone, as a predictor for SPM-MDRPa.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16127037      PMCID: PMC1195411          DOI: 10.1128/AAC.49.9.3663-3667.2005

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  39 in total

1.  Effect of antibiotic therapy on the density of vancomycin-resistant enterococci in the stool of colonized patients.

Authors:  C J Donskey; T K Chowdhry; M T Hecker; C K Hoyen; J A Hanrahan; A M Hujer; R A Hutton-Thomas; C C Whalen; R A Bonomo; L B Rice
Journal:  N Engl J Med       Date:  2000-12-28       Impact factor: 91.245

Review 2.  Methodological principles of case-control studies that analyzed risk factors for antibiotic resistance: a systematic review.

Authors:  A D Harris; T B Karchmer; Y Carmeli; M H Samore
Journal:  Clin Infect Dis       Date:  2001-03-21       Impact factor: 9.079

3.  Influence of previous exposure to antibiotic therapy on the susceptibility pattern of Pseudomonas aeruginosa bacteremic isolates.

Authors:  E B El Amari; E Chamot; R Auckenthaler; J C Pechère; C Van Delden
Journal:  Clin Infect Dis       Date:  2001-10-24       Impact factor: 9.079

4.  Emergence of IMP-4 metallo-beta-lactamase in a clinical isolate from Australia.

Authors:  Anton Y Peleg; Clare Franklin; Jan Bell; Denis W Spelman
Journal:  J Antimicrob Chemother       Date:  2004-07-28       Impact factor: 5.790

5.  Nosocomial outbreak of carbapenem-resistant Pseudomonas aeruginosa with a new bla(IMP) allele, bla(IMP-7).

Authors:  Alan Patrick Gibb; Chanwit Tribuddharat; Richard A Moore; Thomas J Louie; Wally Krulicki; David M Livermore; Marie-France I Palepou; Neil Woodford
Journal:  Antimicrob Agents Chemother       Date:  2002-01       Impact factor: 5.191

6.  Occurrence of a new metallo-beta-lactamase IMP-4 carried on a conjugative plasmid in Citrobacter youngae from the People's Republic of China.

Authors:  P M Hawkey; J Xiong; H Ye; H Li; F H M'Zali
Journal:  FEMS Microbiol Lett       Date:  2001-01-01       Impact factor: 2.742

Review 7.  Impact of antibiotic resistance on clinical outcomes and the cost of care.

Authors:  M S Niederman
Journal:  Crit Care Med       Date:  2001-04       Impact factor: 7.598

8.  Contemporary assessment of antimicrobial susceptibility testing methods for polymyxin B and colistin: review of available interpretative criteria and quality control guidelines.

Authors:  A C Gales; A O Reis; R N Jones
Journal:  J Clin Microbiol       Date:  2001-01       Impact factor: 5.948

9.  Metallo-beta-lactamases in clinical Pseudomonas isolates in Taiwan and identification of VIM-3, a novel variant of the VIM-2 enzyme.

Authors:  J J Yan; P R Hsueh; W C Ko; K T Luh; S H Tsai; H M Wu; J J Wu
Journal:  Antimicrob Agents Chemother       Date:  2001-08       Impact factor: 5.191

10.  Purification and biochemical characterization of the VIM-1 metallo-beta-lactamase.

Authors:  N Franceschini; B Caravelli; J D Docquier; M Galleni; J M Frère; G Amicosante; G M Rossolini
Journal:  Antimicrob Agents Chemother       Date:  2000-11       Impact factor: 5.191

View more
  13 in total

1.  Efficacy of tachyplesin III, colistin, and imipenem against a multiresistant Pseudomonas aeruginosa strain.

Authors:  Oscar Cirioni; Roberto Ghiselli; Carmela Silvestri; Wojciech Kamysz; Fiorenza Orlando; Federico Mocchegiani; Fabio Di Matteo; Alessandra Riva; Jerzy Lukasiak; Giorgio Scalise; Vittorio Saba; Andrea Giacometti
Journal:  Antimicrob Agents Chemother       Date:  2007-04-02       Impact factor: 5.191

2.  Biofilm formation, antibiotic susceptibility and RAPD genotypes in Pseudomonas aeruginosa clinical strains isolated from single centre intensive care unit patients.

Authors:  Martina Vaněrková; Barbora Mališová; Iva Kotásková; Veronika Holá; Filip Růžička; Tomáš Freiberger
Journal:  Folia Microbiol (Praha)       Date:  2017-04-01       Impact factor: 2.099

3.  Detection of metallo-beta-lactamase producing Pseudomonas aeruginosa in intensive care units.

Authors:  Arunava Kali; Sreenivasan Srirangaraj; Shailesh Kumar; Hema A Divya; Akhila Kalyani; Sivaraman Umadevi
Journal:  Australas Med J       Date:  2013-12-31

4.  Study of Antibiotic Resistant Genes in Pseudomonas aeroginosa Isolated from Burns and Wounds.

Authors:  A Rashid Mahmood; N Mansour Hussein
Journal:  Arch Razi Inst       Date:  2022-02-28

Review 5.  A systematic review and meta-analyses show that carbapenem use and medical devices are the leading risk factors for carbapenem-resistant Pseudomonas aeruginosa.

Authors:  Anne F Voor In 't Holt; Juliëtte A Severin; Emmanuel M E H Lesaffre; Margreet C Vos
Journal:  Antimicrob Agents Chemother       Date:  2014-02-18       Impact factor: 5.191

6.  Trends and correlation of antibacterial usage and bacterial resistance: time series analysis for antibacterial stewardship in a Chinese teaching hospital (2009-2013).

Authors:  Y M Zou; Y Ma; J H Liu; J Shi; T Fan; Y Y Shan; H P Yao; Y L Dong
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2014-12-10       Impact factor: 3.267

7.  Systematic surveillance cultures as a tool to predict involvement of multidrug antibiotic resistant bacteria in ventilator-associated pneumonia.

Authors:  P Depuydt; D Benoit; D Vogelaers; J Decruyenaere; D Vandijck; G Claeys; G Verschraegen; S Blot
Journal:  Intensive Care Med       Date:  2007-12-08       Impact factor: 17.440

8.  Molecular and epidemiological characterization of IMP-type metallo-β-lactamase-producing Enterobacter cloacae in a Large tertiary care hospital in Japan.

Authors:  Kayoko Hayakawa; Tohru Miyoshi-Akiyama; Teruo Kirikae; Maki Nagamatsu; Kayo Shimada; Kazuhisa Mezaki; Yuko Sugiki; Emi Kuroda; Shiho Kubota; Nozomi Takeshita; Satoshi Kutsuna; Masayoshi Tojo; Norio Ohmagari
Journal:  Antimicrob Agents Chemother       Date:  2014-04-07       Impact factor: 5.191

Review 9.  Current treatment of pseudomonal infections in the elderly.

Authors:  Georgios Pappas; Kaiti Saplaoura; Matthew E Falagas
Journal:  Drugs Aging       Date:  2009       Impact factor: 3.923

10.  The characteristics of metallo-β-lactamase-producing gram-negative bacilli isolated from sputum and urine: a single center experience in Korea.

Authors:  Bum Sik Chin; Sang Hoon Han; Suk Hoon Choi; Han Sung Lee; Su Jin Jeong; Hee Kyung Choi; Jun Yong Choi; Young Goo Song; Chang Ki Kim; Dongeun Yong; Kyungwon Lee; June Myung Kim
Journal:  Yonsei Med J       Date:  2011-03       Impact factor: 2.759

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.